Remy Cointreau, European Drinks Stocks Jump After Outlook Reassures
By Adria Calatayud
Remy Cointreau shares jumped, sending stocks in European peers like Diageo, Pernod Ricard and Davide Campari-Milano higher, after analysts said the outlook of the French drinks maker offers relief to investors.
At 0855 GMT on Friday, Remy Cointreau shares jumped 13% to EUR99.26, but remained down almost 14% since the beginning of the year. Pernod Ricard was up 6.2%, Campari was up 3.7% and Diageo rose 3.5%.
Remy Cointreau reported sales for the quarter to December of 319.9 million euros ($347 million), down 27% compared with the year-earlier period. On an organic basis, quarterly sales fell 24%, hurt by intense promotional activity in the U.S. cognac market, a weaker-than-expected economic recovery in China from Covid-19 and the effects of inflation on European consumers, it said.
The company said it now expects sales for the year ending in March to fall by close to 20%, at the steeper end of its previously indicated range of 15% to 20%.
Remy Cointreau's confirmed fiscal 2024 guidance should result in some relief, and shares should rebound as investor confidence on a recovery increases, Jefferies analysts Edward Mundy and Andrei Andon-Ionita said in a research note.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
January 26, 2024 04:18 ET (09:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?